Connect
MJA
MJA

Should we screen for lung cancer in Australia?

Mark Hew, Robert G Stirling and Michael J Abramson
Med J Aust 2013; 199 (2): 82-83. || doi: 10.5694/mja13.10439

Systematic screening reduces mortality, but is it the best way to go?

Lung cancer is the leading cause of cancer death in Australia. Late diagnosis of advanced disease contributes to the poor 13% 5-year survival rate associated with lung cancer. However, the recently updated United States National Lung Screening Trial (NLST) showed a 20% survival benefit from early detection with low-dose computed tomography (CT) screening.1,2 In light of these results, should people in Australia at high risk of lung cancer now undergo screening?

  • Mark Hew1
  • Robert G Stirling1
  • Michael J Abramson2

  • 1 Allergy, Asthma and Clinical Immunology Service, The Alfred, Melbourne, VIC.
  • 2 School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, VIC.

Correspondence: m.hew@alfred.org.au

Competing interests:

Michael Abramson has received a grant from Pfizer for an unrelated investigator-initiated study.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.